2016
Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction
Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL, Anand IS. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Journal Of Cardiac Failure 2016, 23: 20-28. PMID: 27317843, DOI: 10.1016/j.cardfail.2016.06.006.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor-binding protein 7Heart failureCause mortalityPrimary outcomeEjection fractionHF eventsInsulin-like growth factorEjection Fraction trialGlomerular filtration rateSigns/symptomsProtein 7Binding protein 7Cardiovascular eventsMultivariable adjustmentSecondary outcomesCardiovascular hospitalizationPrognostic valueFiltration ratePrognostic meritTreatment groupsGrowth factorOutcomesFurther studiesPatientsEGFRThe Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy
Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. JACC Heart Failure 2016, 4: 749-755. PMID: 27179830, DOI: 10.1016/j.jchf.2016.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAmbulatory CareAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDisease ProgressionFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsNatriuretic Peptide, BrainPatient Care PlanningPeptide FragmentsProportional Hazards ModelsSodium Potassium Chloride Symporter InhibitorsStandard of CareTreatment OutcomeConceptsHeart failureChronic HFrEFNT-proBNPEjection fractionN-terminal pro-B-type natriuretic peptide concentrationsHigher loop diuretic dosesAngiotensin-converting enzyme inhibitorB-type natriuretic peptideAmbulatory heart failureAmino-Terminal ProJugular venous distensionLoop diuretic dosesAcute heart failureDecompensated heart failureReduced ejection fractionEvent-free survivalNatriuretic peptide concentrationsHigher ejection fractionStandard of careRelevant clinical eventsDiuretic therapyHF managementCardiovascular deathDiuretic dosesVenous distension
2015
Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea
Alba GA, Truong QA, Gaggin HK, Gandhi PU, De Berardinis B, Magrini L, Bajwa EK, Di Somma S, Januzzi JL, Network G. Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. The American Journal Of Medicine 2015, 129: 96-104.e7. PMID: 26169892, DOI: 10.1016/j.amjmed.2015.06.037.Peer-Reviewed Original ResearchConceptsDiagnosis of pneumoniaNet reclassification improvementEmergency departmentHeart failurePrognostic valueReclassification improvementEmergency department patientsIndependent prognostic informationAccuracy of procalcitoninUrban emergency departmentAccurate diagnostic markerAcute dyspneaClinician certaintyElevated procalcitoninSerum procalcitoninDyspneic patientsProspective cohortSecondary outcomesDepartment patientsProcalcitonin concentrationsFatal outcomeNatriuretic peptidePCT valuesPrognostic utilityPatient populationConcentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, Szymonifka J, Januzzi JL. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal Of Cardiovascular Translational Research 2015, 8: 164-172. PMID: 25777344, DOI: 10.1007/s12265-015-9618-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersChi-Square DistributionChronic DiseaseDisease ProgressionFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardiumNatriuretic Peptide, BrainNecrosisOdds RatioPeptide FragmentsPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsSystoleTime FactorsTroponin IVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLV systolic dysfunctionChronic heart failureHeart failureLV remodelingSerial measurementsHigh-risk clinical featuresLower CV event ratesCV event ratesDeleterious LV remodelingIndependent risk informationPoor cardiovascular outcomesPoor CV outcomesProgressive LV remodelingSensitive cardiac troponinMajority of patientsSignificant myocardial necrosisSensitive troponin assaysPg/mLCV outcomesHsTnI concentrationsCardiovascular eventsCardiovascular outcomesSystolic dysfunctionAdverse remodelingClinical featuresAnalysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure
Gandhi PU, Gaggin HK, Belcher AM, Harisiades JE, Basile A, Falco A, Rosati A, Piscione F, Januzzi JL, Turco MC. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clinica Chimica Acta 2015, 445: 73-78. PMID: 25753466, DOI: 10.1016/j.cca.2015.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdaptor Proteins, Signal TransducingAdrenomedullinAgedAged, 80 and overApoptosis Regulatory ProteinsAtrial Natriuretic FactorBiomarkersErbB ReceptorsFemaleGene ExpressionHeart FailureHeart VentriclesHumansInterleukin-1 Receptor-Like 1 ProteinKidney Function TestsMalePrognosisReceptors, Cell SurfaceStroke VolumeSurvival AnalysisConceptsLeft ventricular ejection fractionBcl-2-associated athanogene 3Heart failureNatriuretic peptidePlasma concentrationsCox proportional hazards regressionWorse renal functionVentricular ejection fractionKaplan-Meier analysisProportional hazards regressionSignificant mortality predictorsCox proportional hazardsGenesis of cardiomyopathyHF prognosisHF patientsBaseline characteristicsPrimary endpointRenal functionEjection fractionHazards regressionMortality predictorsVital statusPrognostic valuePatientsProportional hazardsGalectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF
2014
Clinical Impact of Atrial Fibrillation in Patients With the HeartMate II Left Ventricular Assist Device
Enriquez AD, Calenda B, Gandhi PU, Nair AP, Anyanwu AC, Pinney SP. Clinical Impact of Atrial Fibrillation in Patients With the HeartMate II Left Ventricular Assist Device. Journal Of The American College Of Cardiology 2014, 64: 1883-1890. PMID: 25444141, DOI: 10.1016/j.jacc.2014.07.989.Peer-Reviewed Original ResearchConceptsParoxysmal atrial fibrillationAtrial fibrillationHF hospitalizationThromboembolic eventsVentricular assist deviceHeartMate IIHMII LVADAssist deviceImpact of AFCox proportional hazards regressionEffect of AFKaplan-Meier survival analysisHigh INR levelsHeart failure hospitalizationMajor bleeding eventsPersistent atrial fibrillationProportional hazards regressionBleeding eventsHMII implantationINR levelsFailure hospitalizationPatient yearsComposite endpointIndependent predictorsClinical outcomesCharacterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study
Gandhi PU, Szymonifka J, Motiwala SR, Belcher AM, Januzzi JL, Gaggin HK. Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal Of Cardiac Failure 2014, 21: 9-15. PMID: 25463415, DOI: 10.1016/j.cardfail.2014.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersCardiovascular AgentsChronic DiseaseDisease ManagementDizzinessFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsProspective StudiesQuality of LifeRenal InsufficiencySurveys and QuestionnairesTreatment OutcomeConceptsTreatment-related serious adverse eventsSerious adverse eventsQuality of lifeAdverse eventsRisk scoreN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic heart failure managementHeart Failure Questionnaire scoreWorse QOLAcute renal failureFirst cardiovascular eventHeart failure managementHeart failure therapyWorse functional classHighest-risk quartileCare armHF careHF managementSystolic HFCardiovascular eventsNT-proBNPReverse remodelingFailure therapyRenal failure